Olema Pharmaceuticals, Inc.
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$162.5M
- Total assets
- $533.4M
- Market cap
- $900.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $178.7M
- Operating income
- -$178.7M
- Income tax
- $3.0K
- Net income
- -$162.5M
- EPS (basic)
- $-1.87
- EPS (diluted)
- $-1.87
Balance sheet
- Total assets
- $533.4M
- Current assets
- $515.5M
- Total liabilities
- $54.9M
- Current liabilities
- $51.8M
- Shareholders’ equity
- $478.6M
Cash flow
- Operating cash flow
- -$146.7M
- Investing cash flow
- -$155.8M
- Financing cash flow
- $211.3M
- Net cash flow
- -$91.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $900.6M
- EPS (diluted)
- $-1.87
- Shares outstanding
- 90.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 19, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $162.5M.
- Trading 72% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Olema Pharmaceuticals, Inc..
Write a review
News about Olema Pharmaceuticals, Inc.
News & sentiment via Polygon.io
